DB:NEL

Stock Analysis Report

Executive Summary

NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally.

Snowflake

Fundamentals

Slightly overvalued with questionable track record.


Similar Companies

Share Price & News

How has NantHealth's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NEL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

12.0%

NEL

2.3%

DE Healthcare Services

0.7%

DE Market


1 Year Return

-44.4%

NEL

20.9%

DE Healthcare Services

9.9%

DE Market

Return vs Industry: NEL underperformed the German Healthcare Services industry which returned 20.9% over the past year.

Return vs Market: NEL underperformed the German Market which returned 9.9% over the past year.


Shareholder returns

NELIndustryMarket
7 Day12.0%2.3%0.7%
30 Day6.1%8.9%5.9%
90 Day34.5%10.5%12.0%
1 Year-44.4%-44.4%21.9%20.9%13.4%9.9%
3 Year-93.0%-93.0%61.4%57.2%25.8%14.7%
5 Yearn/a204.5%191.2%42.6%23.2%

Price Volatility Vs. Market

How volatile is NantHealth's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NantHealth undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NEL (€0.7) is trading below our estimate of fair value (€11.61)

Significantly Below Fair Value: NEL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NEL is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: NEL is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NEL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NEL has negative assets, so we can't compare its PB Ratio to the DE Healthcare Services industry average.


Next Steps

Future Growth

How is NantHealth forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

35.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NEL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NEL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NEL's revenue (12.5% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: NEL's revenue (12.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NEL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has NantHealth performed over the past 5 years?

-13.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEL has high quality earnings.

Growing Profit Margin: NEL's current net profit margins (-105.8%) are higher than last year (-184.2%).


Past Earnings Growth Analysis

Earnings Trend: NEL is unprofitable, and losses have increased over the past 5 years at a rate of -13.6% per year.

Accelerating Growth: Unable to compare NEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (27.6%).


Return on Equity

High ROE: NEL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is NantHealth's financial position?


Financial Position Analysis

Short Term Liabilities: NEL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NEL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NEL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: NEL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: NEL has a low level of unsold assets or inventory.

Debt Coverage by Assets: NEL has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NEL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NEL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is NantHealth's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate NEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NEL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEL's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of NantHealth's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Patrick Soon-Shiong (66yo)

9.3yrs

Tenure

0

Dr. Patrick Soon-Shiong, M.D., FRCS (C), FACS, MBBCh, MSc, FRCS (C), is an Owner of Los Angeles Times Communications, LLC. Dr. Soon-Shiong is a physician, surgeon and scientist, invented and developed the  ...


Management Age and Tenure

2.1yrs

Average Tenure

54yo

Average Age

Experienced Management: NEL's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

3.5yrs

Average Tenure

67yo

Average Age

Experienced Board: NEL's board of directors are considered experienced (3.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Patrick Soon-Shiong (66yo)

    Founder

    • Tenure: 9.3yrs
  • Ron Louks (54yo)

    COO & Director

    • Tenure: 1.4yrs
    • Compensation: US$718.53k
  • Bobby Reddy

    Chief Medical Officer

    • Tenure: 2.5yrs
  • Brandon Villery

    VP, General Counsel & Corporate Secretary

    • Tenure: 2.1yrs
  • Keith Krebs

    Senior Vice President of Client Services

    • Tenure: 2.1yrs
  • Chris House

    Senior Vice President of Product Development

    • Tenure: 2.1yrs
  • Maureen Becker

    Vice President of Human Resources

    • Tenure: 1.8yrs
  • Bob Petrou (47yo)

    Chief Financial Officer

    • Tenure: 1.2yrs
    • Compensation: US$490.43k
  • Mark Mozley

    Senior VP of Global Sales & Marketing

    • Tenure: 1.8yrs

Board Members

  • Patrick Soon-Shiong (66yo)

    Founder

    • Tenure: 9.3yrs
  • Michael Blaszyk (67yo)

    Independent Director

    • Tenure: 3.5yrs
    • Compensation: US$248.80k
  • Kirk Calhoun (75yo)

    Independent Director

    • Tenure: 3.5yrs
    • Compensation: US$240.05k
  • Michael Sitrick (72yo)

    Independent Director

    • Tenure: 3.5yrs
    • Compensation: US$246.30k
  • Ron Louks (54yo)

    COO & Director

    • Tenure: 1.4yrs
    • Compensation: US$718.53k

Company Information

NantHealth, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NantHealth, Inc.
  • Ticker: NEL
  • Exchange: DB
  • Founded: 2010
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$72.456m
  • Listing Market Cap: US$65.645m
  • Shares outstanding: 110.62m
  • Website: https://nanthealth.com

Number of Employees


Location

  • NantHealth, Inc.
  • 9920 Jefferson Boulevard
  • Culver City
  • California
  • 90232
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NHNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2016
NELDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2016

Biography

NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/11 21:39
End of Day Share Price2019/11/11 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.